Table of Contents
- Trial overview
- Diffuse large B-cell lymphoma studies
- Other B-cell malignancy studies
- Pediatric and young adult study
- Main endpoints being measured
- Who may be able to join
Trial overview
Clinical trials of Zilovertamab Vedotin are studying this treatment in people with lymphoma and other B-cell cancers.[1] The studies include Phase 1, Phase 2, Phase 3, and Phase 4 trials, which means the research ranges from early safety testing to larger comparison studies.[1][2]
Across the trials, researchers are mainly checking safety, tolerability, and how well the treatment works.[1][2] Some studies test Zilovertamab Vedotin alone, while others test it together with standard treatment such as R-CHP, R-CHOP, R-GemOx, BR, or nemtabrutinib.[1][2]
Diffuse large B-cell lymphoma studies
Several trials focus on diffuse large B-cell lymphoma (DLBCL), which is the most common cancer group studied in this set of trials.[1][2] One Phase 2 study is looking at Zilovertamab Vedotin with R-CHP in 50 participants and is measuring dose-limiting toxicities, adverse events, treatment stopping because of adverse events, and complete response rate.[1]
A larger Phase 3 study is comparing Zilovertamab Vedotin plus R-CHP with R-CHOP in 1,146 participants with DLBCL, and its main endpoint is progression-free survival.[2] Another Phase 2 study is comparing Zilovertamab Vedotin plus R-CHP with polatuzumab vedotin plus R-CHP in 594 participants, using complete response rate at the end of treatment as the main endpoint.[6]
One completed Phase 2 study included 134 people with DLBCL who had failed prior therapies and measured objective response rate.[4] Another authorised Phase 4 study is testing Zilovertamab Vedotin with R-GemOx or BR in 317 participants with relapsed or refractory DLBCL, and it measures dose-limiting toxicities, adverse events, treatment discontinuation due to adverse events, overall survival, and progression-free survival.[5]
Other B-cell malignancy studies
One Phase 2 study is looking at Zilovertamab Vedotin in adults with aggressive and indolent B-cell malignancies, including mantle cell lymphoma, chronic lymphocytic leukemia, follicular lymphoma, and Richter’s syndrome.[7] This study also includes combinations with nemtabrutinib, depending on the cohort, and measures safety and objective response rate using different response rules for different diseases.[7]
In this study, the main results include adverse events, treatment discontinuation because of adverse events, dose-limiting toxicities in mantle cell lymphoma, and objective response rate for several cohorts.[7] The study is important because it includes more than one disease type and more than one treatment plan, so the results may help researchers understand where the treatment may fit best.[7]
Pediatric and young adult study
One Phase 1 substudy is designed for pediatric and young adult participants with hematologic malignancies or solid tumors.[3] The study includes participants from birth to under 18 years for several cancers, and from birth to 25 years for Ewing sarcoma.[3]
This trial is mainly checking safety and tolerability of Zilovertamab Vedotin given by itself in younger participants.[3] It also looks at preliminary antitumor activity, which means early signs that the treatment may shrink or control the cancer.[3]
The cancers in this substudy include B-cell acute lymphoblastic leukemia, DLBCL or Burkitt lymphoma, neuroblastoma, and Ewing sarcoma.[3] Because this is an early study, the main goal is to learn whether the treatment can be given safely and whether there are signs it may help.[3]
Main endpoints being measured
Trial endpoints are the main results researchers plan to measure.[1][2][3][4][5][6][7]
Dose-limiting toxicity (DLT) means a side effect that is serious enough to limit treatment, and it is used in early studies to help choose a safe dose.[1][3][5][7]
Adverse event (AE) means any unwanted medical problem during the study, even if it is not clearly caused by the treatment.[1][3][5][7]
Complete response rate (CRR) shows the percentage of people whose cancer signs disappear after treatment.[1][6]
Objective response rate (ORR) measures how many participants have a meaningful shrinkage of their cancer or a clear treatment response.[3][4][7]
Progression-free survival (PFS) is the length of time the cancer does not get worse after treatment starts.[2][5]
Overall survival (OS) measures how long participants are alive after treatment begins.[5]
Lugano Response Criteria is a standard way to judge how well lymphoma treatment is working.[1][2][4][5][6]
Blinded Independent Central Review (BICR) means a separate review of results by experts who do not know which treatment the participant received.[2][4][5][6]
Who may be able to join
Each trial has its own rules, but the common theme is that participants already have a blood cancer diagnosis or a related solid tumor diagnosis.[1][2][3][4][5][6][7]
Some studies are for adults with newly diagnosed DLBCL, while others are for people whose cancer came back or did not respond to earlier treatment.[4][5] The pediatric substudy includes younger patients, showing that research is also being done in children, teenagers, and young adults.[3]
Because these are clinical trials, joining is not automatic, and people must meet the specific study requirements for age, diagnosis, and treatment history.[1][2][3][4][5][6][7]
